| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b20739bab673a339d5729afd503c1232 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4702
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4747
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6455 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00 |
| filingDate |
2018-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d2087bde8d8eb12ef94190344049957
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f0151e16ab9135e07519d1aa756c104
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a177b247609a9c5c6f981c0cffc41757 |
| publicationDate |
2020-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3658158-A1 |
| titleOfInvention |
Smac/diablo inhibitors useful for treating cancer |
| abstract |
The present invention relates to compositions and methods for the treatment of cancer, particularly agents that inhibit the expression and / or activity of the second proteinase mitochondrial activator of the caspase / direct inhibitor of the binding protein. apoptotic with low pI (SMAC / Diablo). Inhibitory agents include RNA interference molecules blocking the expression of SMAC / Diablo and peptides modulating its interactions in the cell nucleus and mitochondria. The methods and agents of the present invention are useful in the treatment of cancers associated with SMAC / Diablo overexpression. |
| priorityDate |
2017-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |